Glycolic acid, TCA among FDA's proposed additions to 503B bulk drugs list
Four new bulk substances are up for inclusion on the list of active pharmaceutical ingredients that outsourcing facilities can use in drug compounding under section 503B of the Federal Food, Drug, and Cosmetic Act, according to a proposal from the FDA.
The four substances FDA is proposing to include as bulk drug substances are diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester and trichloroacetic acid. An additional 19 bulk drug substances were considered for inclusion in the 503B bulk drug substances list, but FDA is proposing not to include these substances, citing a lack of clinical need for an outsourcing facility to compound drugs from the 19 substances. This lack of need, said the agency, meant the drugs did not meet the statutory criteria for addition to the list.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.